Close

BIO Submits Testimony for Hearing on Recently Expired Tax Credits

Mar 14 2018
BIO submitted written testimony to the U.S. House Ways and Means Subcommittee on Tax Policy, for the hearing “Post Tax Reform Evaluation of Recently Expired Tax Provisions,” asking the committee to provide a seamless multi-year extension of the Second Generation Biofuel Producer Tax Credit; the Special Depreciation Allowance for Second Generation Biofuel Plant Property; the Biodiesel and Renewable Diesel Fuels Credit; and the Alternative Fuel Vehicle Refueling Property, which Congress recently extended retroactively for 2017 but are currently expired.

Oregon Governor Signs Misleading Drug Pricing Bill

Mar 13 2018
BIO regrets signing of misleading drug pricing and reporting bill by Oregon Governor Brown, as it will fail to provide patients the lower drug costs they were promised

BIO is Now Accepting Nominations for the 2018 Rosalind Franklin Award

Mar 13 2018
Washington, D.C. (March 13, 2018) - Each year, the Biotechnology Innovation Organization (BIO) presents the Rosalind Franklin Award for Leadership in Industrial Biotechnology to an outstanding woman in the industrial biotechnology sector who has made significant contributions to the advancement of the biobased economy and biotech innovation. BIO is now accepting nominations for the 2018 Rosalind Franklin Award. The award will be presented at the 2018 World Congress on Industrial Biotechnology in Philadelphia at the Pennsylvania Convention Center from July 16-19, 2018. The deadline to submit nominations is March 28, 2018. 

International Council of Biotech Associations Launches New Website

Mar 12 2018

Washington, D.C. (March 12, 2018) – The International Council of Biotech Associations (ICBA) today announced the launch of

GREENER Fuels Act Would Undermine Investment in Advanced Biofuels, BIO Says

Mar 8 2018
BIO voiced its opposition to the GREENER Fuels Act, introduced by Sen. Tom Udall (D-NM) and Rep. Peter Welch (D-VT), because it would revise the Renewable Fuel Standard (RFS) in way that will chill investment in advanced biofuel.

BIO Applauds Introduction of the Ensuring the Value of the 340B Program Act of 2018

Mar 1 2018
Washington, DC (March 1, 2018) – BIO President and CEO Jim Greenwood issued the following statement today regarding the introduction by Senator Charles Grassley of S. 2453, the Ensuring the Value of the 340B Program Act of 2018:

BIO Selects Des Moines as Venue for the 2019 BIO World Congress on Industrial Biotechnology

Feb 26 2018
The Biotechnology Innovation Organization (BIO) today announced the selection of Des Moines, Iowa, as the location for the 2019 BIO World Congress on Industrial Biotechnology. The event will be held July 8-11, 2019 and it will host industry executives, investors, policy makers and academics from around the world and will feature the BIO One-on-One Partnering™ system.

BIO Statement on President’s Proposed 2019 Budget

Feb 13 2018
Washington, D.C. (February 13, 2018) — Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood issued the following statement in response to President Trump’s FY 2019 budget proposal.

BIO Expresses Strong Support for TRID Improvement Act

Feb 12 2018
Legislation provides critical regulatory relief to small, pre-revenue emerging companies Washington, D.C. (February 12, 2018)— The Biotechnology Innovation Organization (BIO) announced its strong support today for H.R. 3978, the TRID Improvement Act. The bill includes a provision known as the Fostering Innovation Act, which offers much needed regulatory relief to small biotechnology firms. 

BIO Releases Report on State of Innovation for Pain and Addiction Therapeutics

Feb 12 2018
Report highlights the need to stimulate innovation to battle the opioid epidemic Washington, DC (February 12, 2018) – Today, the Biotechnology Innovation Organization (BIO) released a new report, The State of Innovation in Highly Prevalent Chronic Diseases: Pain and Addiction Therapeutics. While many promising treatment approaches are in development, lower investment and pipeline breadth in pain and addiction relative to other disease areas with high societal health burdens demonstrates the need for incentivizing more research and clinical development in these areas.